HOME ·

CSPC PHARMA

CSPC PHARMA (01093.HK): Phase II clinical trial of SYH2085 tablets for uncomplicated influenza in adults officially initiated in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-09-07
CSPC PHARMA (01093.HK): ADC candidate SYS6010 receives another Breakthrough Therapy designation in China for recurrent or metastatic head and neck squamous cell carcinoma
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-01
CSPC PHARMA (01093.HK): Phase I clinical trial of SYH2056 tablets for major depressive disorder officially initiated in China
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-01
CSPC PHARMA (01093.HK): Phase I clinical trial of SYH2092 for weight management initiated in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-09-01
CSPC PHARMA (01093.HK): Phase II Clinical Trial of SYH2069 Injection for Weight Management in Overweight or Obese Adults Launched at First Study Site in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-08-28
CSPC PHARMA (01093.HK): High-potency amylin receptor agonist SYH2092 injection approved for clinical trials in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-08-27
CSPC PHARMA (01093.HK): SYS6090 granted FDA Fast Track designation for MSS/pMMR metastatic colorectal cancer
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-08-26
CSPC PHARMA (01093.HK): SYS6010 meets primary endpoint in Phase III study for EGFR-mutant NSCLC after EGFR TKI failure
Tags：
CSPC PHARMA01093.HKR&D ProgressClinical Trial
2026-08-26
CSPC PHARMA (01093.HK): Recombinant respiratory syncytial virus vaccine SYS6057 approved for clinical trials in the US
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-08-25
CSPC PHARMA(01093.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 6.09 billion, YoY increase of 139.19%
Tags：
CSPC PHARMA01093.HKprofit growth
2026-08-20
CSPC PHARMA (01093.HK): NDA for KN026 Plus HB1801 as First-Line Treatment for Advanced Breast Cancer Accepted by NMPA
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-08-18
CSPC PHARMA(01093.HK): Receives USD10‑Million Milestone Payment from AstraZeneca
Tags：
CSPC PHARMA01093.HKAstraZenecastrategic cooperation
2026-08-05
CSPC PHARMA(01093.HK): Joint Venture Established with AstraZeneca, Holding 51% Stake to Co‑Build Biologics Manufacturing Base
Tags：
CSPC PHARMA01093.HKAstraZenecajoint‑venture company
2026-08-05
CSPC PHARMA(01093.HK): NDA for Neoadjuvant Therapy of Anitumab Combined with HB1801 in HER2‑positive Breast Cancer Accepted and Granted Priority Review
Tags：
CSPC PHARMA01093.HKALPHAMAB-BNew Drug Application
2026-08-04
CSPC PHARMA(01093.HK): Phase Ib/II Clinical Trial of SYS6090 Injection for Colorectal Cancer Initiated at First Study Centre in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-08-03
CSPC Pharmaceutical (01093.HK): SYH2062 Hypertension Phase II Trial Initiated at First China Site; CRB-701 FDA Cleared for Pivotal OPSCC Trial
Tags：
CSPC PHARMA01093.HK
2026-07-29
CSPC Pharmaceutical (01093.HK): NDA for Sirolimus Albumin-Bound Injection Accepted by NMPA with Breakthrough Therapy and Priority Review Status
Tags：
CSPC PHARMA01093.HK
2026-07-27
CSPC Pharmaceutical (01093.HK): Paliperidone Palmitate Injection Approved for Marketing; Indicated for Schizophrenia Acute and Maintenance Treatment
Tags：
CSPC PHARMA01093.HK
2026-07-24
CSPC PHARMA (01093.HK): NDA for Envi Trastuzumab Injection Accepted by NMPA
Tags：
CSPC PHARMA01093.HKNew Drug Application
2026-07-17
CSPC PHARMA(01093.HK): Phase II Clinical Trial of SYH2070 Injection for Mixed Hyperlipidaemia Initiated at First Clinical Site in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-07-07
Previous1 23